NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
Status:
Not yet recruiting
Trial end date:
2023-03-25
Target enrollment:
Participant gender:
Summary
This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and
effectiveness of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory
NKG2DL+ solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School